Republic of the Philippines
Department of Health
METRO MANILA CENTER FOR HEALTH DEVELOPMENT

SUPPLEMENTAL/ BID BULLETIN NO. 1

IB 2022 - 043

PROCUREMENT OF 850,305 CYCLE OF LEVONORGESTREL + ETHINYLESTRADIOL ORAL TABLETS

This Supplemental/Bid Bulletin No. 1 is being issued to revise provisions/specifications in the Bidding Documents for a forecited project:

Revision and clarification to provisions/specifications in the Bidding Documents:	
FROM	**TO**
Last seven tablets placebo or ferrous	

The revised Technical Specification form is enclosed for the prospective bidder's reference and use

Bidders are advised to use the following attached forms and submit together with all required documents for the submission of bids on 7th day of March 2022, 9:00 AM:

This Supplemental/Bid Bulletin No. 1 shall form an integral part of the Bidding Documents. All other provisions indicated in the bidding documents which are not affected by this Supplemental/Bid Bulletin No. 1 shall remain in effect.

For guidance and information of all concerned.

Issued this 22nd day of February, 2022 in MMCHD

Approved by:

ALELI ANNIE GRACE P. SUDIACAL, MD, MPH
Director III / BAC Chairperson

Section VI. Schedule of Requirements

The delivery schedule expressed as weeks/months stipulates hereafter a delivery date which is the date of delivery to the project site.

Item Number	Description	Quantity	Total ABC (Php)	Delivery Site	Delivered, Weeks/Months
1	PROCUREMENT OF 850,305 CYCLE OF LEVONORGESTREL + ETHINYLESTRADIOL ORAL TABLETS	850,305	34,012,200.00	DOH-MMCHD Pasig Warehouse	90-120 calendar days

Technical Specifications

Item	Specification	Statement of Compliance
		[Bidders must state here either "Comply" or "Not Comply" against each of the individual parameters of each Specification stating the corresponding performance parameter of the equipment offered. Statements of "Comply" or "Not Comply" must be supported by evidence in a Bidders Bid and cross-referenced to that evidence. Evidence shall be in the form of manufacturer's un-amended sales literature, unconditional statements of specification and compliance issued by the manufacturer, samples, independent test data etc., as appropriate. A statement that is not supported by evidence or is subsequently found to be contradicted by the evidence presented will render the Bid under evaluation liable for rejection. A statement either in the Bidder's statement of compliance or the supporting evidence that is found to be false either during Bid evaluation, post-qualification or the execution of the Contract may be regarded as fraudulent and render the Bidder or supplier liable for prosecution subject to the applicable laws and issuances.]
IB 2022 – 043	**PROCUREMENT OF 850,305 CYCLE OF LEVONORGESTREL + ETHINYLESTRADIOL ORAL TABLETS** ABC: 34,012,200.00 Specifications: >oral tablets coated >30 microgram Ethinylestradiol + 150 microgram Levonorgestrel >28 tablets per cycle >Last seven tablets placebo or ferrous Packaging Instructions: 1 cycle per blister pack Secondary Packaging Standard packaging of the manufacturer as approved by PFDA including product insert or encryption/imprint inside the box Shelf Life Must be fresh commercial stock with a total shelf life of Sixty (60) months upon manufacture and (55) months from the date of delivery. Labelling Instructions: >Standard labeling instruction as approved by PFDA pursuant to Administrative Order No. 2016-0008 >On each box, the following shall be imprinted or stickered with non-removable or permanent sticker or label that is binding, and with residue and tearing, if removed: >In addition to the labeling requirements of PFDA: Philippine Government Property – Department of Health NOT FOR SALE Date of Manufacture: Date of Expiry: Batch/Lot No.: Delivery Schedule: >90-120 calendar days (CD) Delivery site: >DOH-MMCHD Pasig Warehouse Additional Technical Documents: Valid PFDA Certificate of Product Registration (CPR) or Valid Extension PFDA License to Operate (LTO) for Drugs Distributors and Traders Product insert/ Product Information Certificate from the manufacturer/main distributor that Bidder is an authorized dealer/exclusive distributor of the product FDA Test Analysis: >The minimum number of the sample units required for each test analysis of delivered medicines shall be based on the PFDA Circular 2014-014	